Rigel Pharmaceuticals
NasdaqGS:RIGL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
WA
Consensus Narrative from 6 Analysts
Advancing Pipeline And Partnerships Will Drive Future Success
Key Takeaways Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE. Strategic collaborations and international partnerships position Rigel for expanded market reach and potential revenue gains through innovative therapies.
View narrativeUS$30.50
FV
34.1% undervalued intrinsic discount15.75%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative